Abstract

Chemogenomics is an emerging discipline that combines the latest tools of genomics and chemistry and applies them to target and drug discovery. Its strength lies in eliminating the bottleneck that currently occurs in target identification by measuring the broad, conditional effects of chemical libraries on whole biological systems or by screening large chemical libraries quickly and efficiently against selected targets. The hope is that chemogenomics will concurrently identify and validate therapeutic targets and detect drug candidates to rapidly and effectively generate new treatments for many human diseases.

Author affiliations

1. Division of Oncology, Stanford University School of Medicine, 269 Campus Drive, CCSR-1110, Stanford, California 94305-5151, USA.
2. Department of General Neurosurgery — Neurocenter, University of Freiburg, Breisacher Str. 64, D-79106 Freiburg, Germany.
3. Novartis Institutes for Biomedical Research, Discovery Technologies, Molecular and Library Informatics Program, CH-4002 Basel, Switzerland.

Correspondence to: Markus Bredel^1,2 Email: mbredel@stanford.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.